Cue Biopharma Reports Phase 2 CSU Durability Data and CUE-401 First-in-Human Dosing
Cue Biopharma's Phase 2 CSU data show durable IgE suppression 12 weeks post-dose; CUE-401 enters first-in-human dosing in Q3 2026.

Formulation scientists and biologics manufacturing leads tracking next-generation anti-IgE programs should note that Cue Biopharma has reported Phase 2 durability findings for CUE-221 in chronic spontaneous urticaria (CSU) alongside the initiation of first-in-human dosing for CUE-401, its dual-agonist autoimmune candidate, marking two concurrent clinical inflection points in Q3 2026.
The Phase 2 CSU data show that durable complete hives resolution (HSS7=0) at week 28, observed 12 weeks after the final dose in the 4 mg/kg cohort, persisted in the absence of clinically meaningful drug exposure. That dissociation between exposure and effect implicates biological activity beyond IgE neutralization alone, consistent with CUE-221's dual mechanism: simultaneous IgE neutralization and suppression of new IgE synthesis. A post-hoc comparison against omalizumab (XOLAIR) showed significantly greater durable response at the 4 mg/kg dose, though post-hoc analyses carry inherent interpretive limits.
From a pharmacological standpoint, free IgE suppression at 4 mg/kg was rapid and profound: all patients in the intensive PK subgroup reached levels below the limit of quantification within hours of dosing, with more than 90% of the broader population achieving those levels by week 1. The study enrolled patients with a median baseline IgE of 427 ng/mL and a range extending to 7,860 ng/mL, with approximately one-third carrying high baseline IgE at or above 720 ng/mL, a population that falls outside the omalizumab food allergy dosing table. Median free IgE showed progressive attenuation of rebound across successive four-week dosing intervals, a pattern relevant to dosing interval design and formulation strategy.
Cue Biopharma has also disclosed active half-life extension efforts for CUE-221, aimed at reducing dosing frequency. For biologics development teams, half-life extension programs typically introduce formulation complexity around molecular engineering, stability profiling, and comparability assessments under ICH Q5E, considerations that will bear on any future regulatory submission package.
CUE-401, a precision-engineered dual TGF-β agonist positioned as a potential first-in-class candidate for autoimmune indications, entered Phase 1 with first-in-human dosing initiated in Q3 2026. The company characterizes this as its first autoimmune therapeutic candidate to reach the clinic. Q3 operating results reflect increased expenditures tied to clinical program initiation and non-cash charges, consistent with the dual-program ramp.
The durability profile emerging from the 4 mg/kg cohort, and the trajectory of the half-life extension program, will be the measurable checkpoints to watch as Cue Biopharma advances toward a food allergy indication and prepares future regulatory submissions for CUE-221.
Source: Cue Biopharma via GlobeNewswire, November 16, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
IDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas

Genentech Gains FDA Approval for Giredestrant Plus Everolimus in Breast Cancer

Discussion